MM-121 is a fully human monoclonal antibody that targets ErbB3.
The study is intended to assess the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab and irinotecan in patients with advanced colorectal cancer, squamous cell head and neck cancer, non-small cell lung cancer, triple negative breast cancer, or other types of solid tumors that depend on epidermal growth factor receptor (EGFR) activity.
The first patient was enrolled at the Huntsman Cancer Institute at the US-based University of Utah.
Merrimack entered a global collaboration and licensing agreement with Sanofi for MM-121 in 2009.